DNM1L and pulmonary arterial hypertension: Some Drp1 inhibitors have shown significant effects in PAH preclinical and clinical trials, such as restoring mitochondrial function and inhibiting the PAH development (Parra et al., 2017; Tian et al., 2018; Zhuan et al., 2020; Wu et al., 2021).